Deep Genomics vs Harrison.ai

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Deep Genomics employs 100-500 people, while Harrison.ai has 100-500 employees.

Deep Genomics has raised more in total funding at $180M, compared to Harrison.ai's $129M — a gap of $51M.

Both Deep Genomics and Harrison.ai share the same Awaira Score of 68/100. The Awaira Score is a composite metric that factors in valuation, total funding raised, company stage, employee count, and market category.

Deep Genomics was founded by Brendan Frey in 2015. Harrison.ai was founded by Aengus Tran in 2018. Visit each company's profile on Awaira for a full founder biography.

Deep Genomics: Deep Genomics applies deep learning to genetic medicine discovery, using AI models trained on genomic sequence data to predict the functional consequences of genetic variants, identify RNA splicing defects that underlie genetic diseases, and generate novel therapeutic candidates including antisense oligonucleotides and small molecules that correct disease-causing genetic variants. The Toronto company was founded by Brendan Frey, a University of Toronto machine learning professor who collaborated with Geoffrey Hinton on deep learning research.\n\nThe company raised approximately $180 million in venture funding from investors including True Ventures, AlleyCorp, and GV (Google Ventures). Deep Genomics has built an AI drug discovery platform called the AI Workbench that integrates genomic data, disease biology, and AI prediction across the therapeutic discovery pipeline, and has entered a strategic alliance with Agenus to develop cancer treatments using its AI-designed oligonucleotide candidates.\n\nDeep Genomics competes in the AI genetic medicine space against Recursion Pharmaceuticals, Insitro, Exscientia, and gene therapy companies building computational biology capabilities. Its specific focus on RNA biology and oligonucleotide therapeutics, which represent a growing class of approved genetic medicines, differentiates it from platforms focused on small molecule drug discovery or cell therapy. The Toronto University of Toronto AI ecosystem, including connections to the Vector Institute and the Hinton research lineage, provides research credibility and talent access that distinguishes Canadian AI drug discovery from international competitors. Harrison.ai: Harrison.ai develops AI radiology and pathology analysis software for clinical deployment, building FDA-cleared and TGA-registered algorithms for chest X-ray abnormality detection, CT pulmonary angiography analysis, and mammography screening under its Annalise.ai product brand. The Sydney company focuses on AI clinical decision support that helps radiologists prioritise worklists, detect abnormalities, and reduce reporting errors in high-volume radiology departments.\n\nThe company raised approximately $129 million including a Series C from investors including Blackbird Ventures, Skip Capital, and Telstra Ventures. Harrison.ai has deployed its Annalise.ai platform across Australian hospital networks and has received US FDA clearance for its chest X-ray AI product, enabling international commercial expansion beyond Australia. The company has published clinical validation studies demonstrating AI performance that is non-inferior to specialist radiologist reads on chest X-ray abnormality detection across multiple institutions.\n\nHarrison.ai competes in the AI radiology market against Aidoc, Lunit, Qure.ai, and Behold.ai, which all target radiologist workflow assistance and clinical alerting. The Australian healthcare market provides a strong home base given the National Health Service framework and centrally coordinated radiology procurement, while FDA clearance opens the substantially larger US radiology AI market. The company is considered one of Australia most promising medical AI companies and a flagship for the Australian healthcare technology ecosystem.

Deep Genomics was founded first in 2015, giving it 3 years of additional market experience. Harrison.ai was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Both Deep Genomics and Harrison.ai report similar employee counts of approximately 100-500. Team size is often a proxy for operational scale, though lean AI companies can punch well above their headcount.

Yes, Deep Genomics and Harrison.ai are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.